Ralph I Horwitz, Sydney Nur Otaka, Allison Hayes Conroy, Mark R Cullen, Adú Matory, Burton H Singer, Ida Sim
{"title":"Biosocial Variation in Treatment Response to GLP-1s: Implications for Clinical Care and Health Policy.","authors":"Ralph I Horwitz, Sydney Nur Otaka, Allison Hayes Conroy, Mark R Cullen, Adú Matory, Burton H Singer, Ida Sim","doi":"10.1016/j.amjmed.2025.05.016","DOIUrl":null,"url":null,"abstract":"<p><p>The potential of GLP-1s to change the trajectory of obesity has ignited enthusiasm for these drugs among physicians, patients, and policymakers. The \"average\" reported weight loss of 20%-25% of body weight has become reified as the \"expected\" benefit for patients with previously treatment-resistant obesity. In our article, we demonstrate the considerable variation around the average treatment response observed in randomized controlled trials, illustrate that the variation is even more pronounced in real-world evidence studies, and examine the role of \"biosocial pathogenesis\" as a possible explanation for the variation. Biosocial pathogenesis examines the role of both biology and biography on physiological systems that affect both the risk for disease and the response to treatment. Research is needed that enables clinical management to be tailored to the biology and \"biography\" of patients with obesity and obesity-related disorders.</p>","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.amjmed.2025.05.016","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
The potential of GLP-1s to change the trajectory of obesity has ignited enthusiasm for these drugs among physicians, patients, and policymakers. The "average" reported weight loss of 20%-25% of body weight has become reified as the "expected" benefit for patients with previously treatment-resistant obesity. In our article, we demonstrate the considerable variation around the average treatment response observed in randomized controlled trials, illustrate that the variation is even more pronounced in real-world evidence studies, and examine the role of "biosocial pathogenesis" as a possible explanation for the variation. Biosocial pathogenesis examines the role of both biology and biography on physiological systems that affect both the risk for disease and the response to treatment. Research is needed that enables clinical management to be tailored to the biology and "biography" of patients with obesity and obesity-related disorders.
期刊介绍：
The American Journal of Medicine - "The Green Journal" - publishes original clinical research of interest to physicians in internal medicine, both in academia and community-based practice. AJM is the official journal of the Alliance for Academic Internal Medicine, a prestigious group comprising internal medicine department chairs at more than 125 medical schools across the U.S. Each issue carries useful reviews as well as seminal articles of immediate interest to the practicing physician, including peer-reviewed, original scientific studies that have direct clinical significance and position papers on health care issues, medical education, and public policy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
